Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

myopia

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients

If approved, Dupixent would be the first drug in the EU indicated for this patient population

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 15,000 people in the US

- PMLiVE

Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment

More than 30,000 new cases of mesothelioma were diagnosed globally in 2022

- PMLiVE

Novartis’ Kisqali combination granted FDA approval for early breast cancer patients

The drug is already approved for certain cases of advanced or metastatic breast cancer

- PMLiVE

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS

The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion

- PMLiVE

Sanofi/Regeneron’s Dupixent receives FDA approval for adolescents with CRSwNP

Approximately 9,000 adolescents in the US are living with inadequately controlled cases of the chronic disease

- PMLiVE

Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin condition occurs in 7.3% of adults in the US

- PMLiVE

Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types

Tecentriq Hybreza can be injected subcutaneously over approximately seven minutes

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

- PMLiVE

Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria

Detailed results from the confirmatory trial will be submitted to the FDA later this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links